X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gastroenterology and hepatology (197) 197
index medicus (154) 154
humans (142) 142
female (121) 121
male (120) 120
middle aged (116) 116
adult (102) 102
hepatitis c, chronic - drug therapy (102) 102
gastroenterology & hepatology (98) 98
hepatitis c virus (90) 90
hepacivirus - genetics (84) 84
hepatitis c (80) 80
ribavirin (80) 80
genotype (74) 74
drug therapy, combination (71) 71
aged (68) 68
antiviral agents - therapeutic use (65) 65
treatment outcome (62) 62
interferon (60) 60
antiviral agents - adverse effects (56) 56
chemistry (54) 54
antiviral agents - administration & dosage (53) 53
genetic aspects (53) 53
metallurgy (53) 53
organic chemistry (53) 53
hepatitis c, chronic - virology (51) 51
care and treatment (50) 50
hepatitis (50) 50
health aspects (49) 49
antiviral agents (48) 48
sofosbuvir (48) 48
abridged index medicus (47) 47
human necessities (43) 43
hygiene (43) 43
medical or veterinary science (43) 43
heterocyclic compounds (41) 41
ribavirin - therapeutic use (41) 41
young adult (40) 40
preparations for medical, dental, or toilet purposes (39) 39
double-blind method (38) 38
ribavirin - administration & dosage (38) 38
specific therapeutic activity of chemical compounds ormedicinal preparations (38) 38
telaprevir (38) 38
cirrhosis (36) 36
hepacivirus - drug effects (35) 35
clinical trials (33) 33
therapy (33) 33
viral nonstructural proteins - antagonists & inhibitors (33) 33
drug therapy (32) 32
genotype & phenotype (32) 32
medicine, general & internal (32) 32
plus ribavirin (32) 32
pharmacology & pharmacy (31) 31
liver cirrhosis (30) 30
polyethylene glycols - therapeutic use (30) 30
infections (29) 29
interferon-alpha - therapeutic use (29) 29
liver (29) 29
rna, viral - blood (29) 29
viral load (29) 29
hcv (28) 28
patients (28) 28
analysis (27) 27
interferon-alpha - administration & dosage (27) 27
medical research (27) 27
virus-infection (26) 26
boceprevir (25) 25
ribavirin - adverse effects (25) 25
uridine monophosphate - analogs & derivatives (25) 25
adolescent (24) 24
chronic hepatitis-c (24) 24
genotypes (24) 24
hepatitis c - drug therapy (24) 24
infectious diseases (24) 24
medicine, experimental (24) 24
polyethylene glycols - administration & dosage (24) 24
virology (24) 24
virus diseases (24) 24
fibrosis (23) 23
biological response modifiers (22) 22
proteases (22) 22
infection (21) 21
liver diseases (21) 21
hepacivirus - classification (20) 20
microbiology (20) 20
protease inhibitors (20) 20
recombinant proteins - therapeutic use (20) 20
interferon-alpha - adverse effects (19) 19
polyethylene glycols - adverse effects (19) 19
recombinant proteins - administration & dosage (19) 19
chronic infection (18) 18
combination (18) 18
drug administration schedule (18) 18
antiviral agents - pharmacokinetics (17) 17
combination therapy (17) 17
dose-response relationship, drug (17) 17
hepacivirus - isolation & purification (17) 17
hepatitis c, chronic - complications (17) 17
drug resistance, viral (16) 16
sustained virologic response (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (477) 477
Spanish (39) 39
Portuguese (13) 13
German (7) 7
Korean (3) 3
French (2) 2
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1879 - 1888
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 01/2018, Volume 47, Issue 2, pp. 259 - 267
Summary Background Chronic hepatitis C infection leads to impairment of patient‐reported outcomes (PROs). Treatment with direct‐acting antiviral regimens... 
SUSTAINED VIROLOGICAL RESPONSE | HCV GENOTYPE 1 | CHRONIC LIVER-DISEASE | DECOMPENSATED CIRRHOSIS | PLUS SOFOSBUVIR | WORK PRODUCTIVITY | PHARMACOLOGY & PHARMACY | INFECTION | QUALITY-OF-LIFE | AND-3 CLINICAL-TRIALS | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | Follow-Up Studies | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Clinical Trials, Phase III as Topic | Multicenter Studies as Topic | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Liver Cirrhosis - genetics | Patient Reported Outcome Measures | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Liver Cirrhosis - drug therapy | Self Report | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Randomized Controlled Trials as Topic | Liver Cirrhosis - virology | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Hepatitis C, Chronic - genetics | Sulfonamides - administration & dosage | Medical research | Liver | Impairment | Clinical trials | Chronic infection | Mental depression | Multivariate analysis | Patients | Cirrhosis | Hepatitis | Anxiety | Interferon | Hepatitis C virus | Hepatitis C | Genotypes
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 08/2013, Volume 369, Issue 7, pp. 678 - 679
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1075 - 1086
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 14, pp. 1292 - 1303
Journal Article